Interleukin-38 in colorectal cancer: a potential role in precision medicine

Chen, Feier; Zhang, Feng; Tan, Zhenyu; Hambly, Brett D.; Bao, Shisan; Tao, Kun

doi:10.1007/s00262-019-02440-7

Cited by 23 publications

(45 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Statistics were performed as described previously [18,25], using GraphPad Prism V9. Wilcoxon signed-rank test or Mann-Whitney U was used for comparison between two paired or non-paired groups.…”

Section: Discussionmentioning

confidence: 99%

“…The low and high cut-off values for IL-36α, IL-36β and IL-36γ production were defined by the median of the CRC tissue image unit. The overall survival or survival curves was defined or plotted as previously described [18]. Prognostic factors that influenced survival was determined using Cox's proportional hazards model.…”

Section: Discussionmentioning

confidence: 99%

“…Fifty-three months was the longest survival period for these CRC patients. Tissue arrays with matched non-CRC tissues exhibited a range of different levels of differentiation, invasion and metastasis and were generated in the Department of Pathology, Tongren Hospital, as described previously [18].…”

Section: Demography Of Crc Patients and Samplesmentioning

confidence: 99%

See 2 more Smart Citations

IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?

Chen

Zhang

et al. 2020

BMC Cancer

Self Cite

View full text Add to dashboard Cite

Background and aims: Colorectal cancer (CRC) is a major killer. Host immunity is important in tumorigenesis. Direct comparison among IL-36α, IL-36β and IL-36γ in the prognosis of CRC is unclear. Methods: CRC tissue arrays were generated from colorectostomy samples with TNM stage, invasion depth and the demography of these patients (n = 185). Using immunohistochemistry/histopathology, IL-36α, IL-36β and IL-36γ were determined, in comparison to non-cancer tissues. Results: A significant association was observed between colonic IL-36α, IL-36β or IL-36γ and the presence of cancer (with all P < 0.0001). Using ROC curve analysis, specificity and sensitivity of IL-36α, IL-36β or IL-36γ were confirmed, with area under the curve (AUC) values of 0.68, 0.73 and 0.65, respectively. Significant differences in survival were observed between IL-36α high and IL-36α low (P = 0.003) or IL-36γ high and IL-36γ low (P = 0.03). Survival curves varied significantly when further stratification into subgroups , on the basis of combined levels of expression of two isotypes of IL-36 was undertaken. A significant difference was observed when levels of IL-36α and IL-36β were combined (P = 0.01), or a combination of IL-36α plus IL-36γ (P = 0.002). The subgroups with a combination of IL-36α high plus IL-36β high , or IL-36α high plus IL-36γ low exhibited the longest survival time among CRC patients. In contrast, the subgroups of IL-36α low plus IL-36β high or IL-36α low plus IL-36γ high had the shortest overall survival. Using the log-rank test, IL-36α high expression significantly improved survival in patients with an invasion depth of T4 (P < 0.0001), lymph node metastasis (P = 0.04), TNM III-IV (P = 0.03) or with a right-sided colon tumour (P = 0.02). Similarly, IL-36γ low expression was significantly associated with improved survival in patients with no lymph node metastasis (P = 0.008), TNM I-II (P = 0.03) or with a left-sided colon tumour (P = 0.05). Multivariate analysis demonstrated that among IL-36α, IL-36β and IL-36γ, only IL-36α (HR, 0.37; 95% CI, 0.16-0.87; P = 0.02) was an independent factor in survival, using Cox proportional hazards regression analysis. Conclusion: IL-36α or IL-36γ are reliable biomarkers in predicting the prognosis of CRC during the later or early stages of the disease, respectively. Combining IL-36α plus IL-36γ appears to more accurately predict the postoperative prognosis of CRC patients. Our data may be useful in the management of CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?

Chen

Zhang

et al. 2020

BMC Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…The SPSS 16.0 statistical software package was used for the statistical analysis. Comparison between two groups was performed via Mann-Whitney U test, as described [44,45]. Comparisons among multigroups were performed via Kruskal-Wallis test.…”

Section: Discussionmentioning

confidence: 99%

“…Brie y, all the images were taken by an Olympus BX51 microscope with xed exposure time and light sources to avoid any additional unwanted errors. The quantitative analysis was conducted using ImagePro Plus 7.1 software (Media Cybernetics, Silver Spring, MD) as described by Liu et al [43] [44,45] The positive staining threshold was de ned by an independent pathologist in a double-blind fashion. The de ned threshold was applied to analyse all of the images, using a pre-programmed macro in ImagePro Plus 7.1 software to obtain the objective positive value (pixels) of the staining.…”

Section: Immunohistochemistrymentioning

confidence: 99%

Inverse correlation between Interleukin-34 and gastric cancer, a potential biomarker for prognosis

Liu

Zhang

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background : Gastric cancer (GC) is a malignancy with high morbidity/mortality, partly due to a lack of reliable biomarkers for early diagnosis. It is important to develop reliable biomarker(s) with specificity, sensitivity and convenience for early diagnosis. The role of tumour-associated macrophages (TAMs) and survival of GC patients are controversial. Macrophage colony stimulating factor (MCSF) regulates monocytes/macrophages. Elevated MCSF is correlated with invasion, metastasis and poor survival of tumour patients. IL-34, a ligand of the MCSF receptor, acts as a “twin” to MCSF, demonstrating overlapping and complimentary actions. IL-34 involvement in tumours is controversial, possibly due to the levels of MCSF receptors. While the IL‑34/MCSF/MCSFR axis is very important for regulating macrophage differentiation, the specific interplay between these cytokines, macrophages and tumour development is unclear. Methods : A multi-factorial evaluation could provide more objective utility, particularly for either prediction and/or prognosis of gastric cancer. Precision medicine requires molecular diagnosis to determine the specifically mutant function of tumours, and is becoming popular in the treatment of malignancy. Therefore, elucidating specific molecular signalling pathways in specific cancers facilitates the success of a precision medicine approach. Gastric cancer tissue arrays were generated from stomach samples with TNM stage, invasion depth and the demography of these patients (n=185). Using immunohistochemistry/histopathology, MCSF, IL-34 and macrophages were determined. Results : We found that IL-34 may serve as a predictive biomarker, but not as an independent, prognostic factor in GC; MCSF inversely correlated with survival of GC in TNM III‑IV subtypes. Increased CD68 + TAMs were a good prognostic factor in some cases and could be used as an independent prognostic factor in male T3 stage GC. Conclusion : Our data support the potency of IL-34, MCSF, TAMs and the combination of IL‑34/TAMs as novel biological markers for GC, and may provide new insight for both diagnosis and cellular therapy of GC.

show abstract

The emerging role of IL‐38 in diseases: A comprehensive review

Chen,

Xi,

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

IntroductionInterleukin‐38 (IL‐38) is a new type of anti‐inflammatory cytokine, which is mainly expressed in the immunity‐related organs and is involved in various diseases including cardiovascular and cerebrovascular diseases, lung diseases, viral infectious diseases and autoimmune diseases.AimThis review aims to detail the biological function, receptors and signaling of IL‐38, which highlights its therapeutic potential in related diseases.ConclusionThis article provides a comprehensive review of the association between interleukin‐38 and related diseases, using interleukin‐38 as a keyword and searching the relevant literature through Pubmed and Web of science up to July 2023.

show abstract

Interleukin-38 in colorectal cancer: a potential role in precision medicine

Cited by 23 publications

References 40 publications

IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?

IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?

Inverse correlation between Interleukin-34 and gastric cancer, a potential biomarker for prognosis

The emerging role of IL‐38 in diseases: A comprehensive review

Contact Info

Product

Resources

About